What is the appropriate management for non‑erosive duodenitis?

Management of Non-Erosive Duodenitis

For non-erosive duodenitis, test for H. pylori and provide eradication therapy if positive; if negative or symptoms persist after eradication, treat with empirical acid suppression using a PPI at standard once-daily dosing. 1

Diagnostic Approach

Non-erosive duodenitis typically presents as part of the dyspepsia spectrum. The 2022 British Society of Gastroenterology guidelines provide the clearest framework for management:

Initial Testing Strategy

• Test for H. pylori using either fecal antigen or carbon-urea breath testing (not serology, which has lower specificity) 1
• If H. pylori positive: provide eradication therapy
• If H. pylori negative: proceed to empirical acid suppression

Important caveat: While approximately 5% of dyspepsia in the community is attributable to H. pylori, testing identifies most cases of peptic ulcer disease, for which eradication is extremely efficacious 1

Treatment Algorithm

First-Line Management

1. H. pylori-positive patients:

   • Provide standard eradication therapy (typically PPI-based triple or quadruple therapy)
   • Do NOT routinely confirm eradication in uncomplicated cases, as most patients with dyspepsia have functional dyspepsia where the effect size is smaller 1
   • Eradication is effective for healing erosive duodenitis when present (86% healing rate in one study) 2

2. H. pylori-negative patients OR persistent symptoms after eradication:

   • Empirical PPI therapy at standard once-daily dosing 1
   • This is reasonable because approximately 20% of dyspepsia patients have peptic ulcer or erosive esophagitis, and PPIs are efficacious for both conditions 1
   • PPIs are also effective for functional dyspepsia 1

Dosing and Duration

• Start with standard-dose PPI once daily (e.g., omeprazole 20 mg, lansoprazole 30 mg)
• Assess response at 4-8 weeks 1
• If symptoms controlled: attempt to wean to lowest effective dose or on-demand therapy 1
• Avoid routine twice-daily dosing unless there is documented severe erosive disease 3

Second-Line Options

If symptoms persist despite PPI therapy:

• Tricyclic antidepressants (e.g., amitriptyline 10 mg once daily, titrated to 30-50 mg) as gut-brain neuromodulators 1
• H2-receptor antagonists may be effective, though evidence is weaker than for PPIs 1, 4
• Consider prokinetics if dysmotility symptoms predominate 1

Key Clinical Pitfalls

Do NOT:

• Use H. pylori serology for diagnosis (lower specificity) 1
• Routinely confirm eradication after treatment in uncomplicated cases 1
• Continue long-term PPI without reassessment—if therapy continues beyond 12 months, consider endoscopy with prolonged pH monitoring to confirm appropriateness 5
• Perform routine endoscopic monitoring for disease progression (not shown to improve outcomes) 6

DO:

• Screen for celiac disease if patient has overlapping IBS-type symptoms (increased risk in that population) 1
• Perform endoscopy in patients ≥55 years with treatment-resistant dyspepsia 1
• Consider urgent evaluation in patients ≥55 years with weight loss or alarm features 1

Special Considerations

The research evidence suggests non-erosive duodenitis exists on a spectrum with duodenal ulcer disease 7, 8. Serial endoscopy studies show that 48% of patients with duodenitis ultimately develop ulcers 8, supporting the rationale for H. pylori eradication and acid suppression strategies similar to peptic ulcer management.

Network meta-analysis data from 15 RCTs involving 6,162 patients demonstrated that "test and treat" ranked first for reducing symptoms at 12 months (RR 0.89; 95% CI 0.78-1.0), making it the preferred initial strategy 1

Long-Term Management

• Once symptoms are controlled, titrate PPI to lowest effective dose 3, 6
• Consider on-demand therapy rather than continuous daily dosing 1
• Provide lifestyle counseling on regular aerobic exercise 1
• If PPI therapy extends beyond one year without clear indication, reassess appropriateness 3, 5